Zynerba Pharma CS (ZYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2022 | 12-2021 | 12-2020 | 12-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -35,036 | -37,309 | -51,337 | -32,944 | -39,911 |
| Depreciation Amortization | 219 | 247 | 207 | 134 | 100 |
| Accounts receivable | 8,355 | -538 | 5,571 | -11,169 | 539 |
| Accounts payable and accrued liabilities | 71 | -724 | -2,145 | 210 | 1,103 |
| Other Working Capital | 7,458 | -2,206 | 4,638 | -7,570 | 789 |
| Other Operating Activity | -4,094 | 7,072 | 1,751 | 16,522 | 4,984 |
| Operating Cash Flow | $-23,027 | $-33,458 | $-41,314 | $-34,818 | $-32,397 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -154 | -48 | -445 | -129 | -287 |
| Investing Cash Flow | $-154 | $-48 | $-445 | $-129 | $-287 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 6,557 | 43,242 | 31,707 | 47,097 | 32,500 |
| Other Financing Activity | -543 | -1,086 | -854 | -1,850 | -2,563 |
| Financing Cash Flow | $6,014 | $42,156 | $30,853 | $45,247 | $29,938 |
| Beginning Cash Position | 67,808 | 59,157 | 70,063 | 59,764 | 62,510 |
| End Cash Position | 50,641 | 67,808 | 59,157 | 70,063 | 59,764 |
| Net Cash Flow | $-17,167 | $8,651 | $-10,906 | $10,300 | $-2,747 |
| Free Cash Flow | |||||
| Operating Cash Flow | -23,027 | -33,458 | -41,314 | -34,818 | -32,397 |
| Capital Expenditure | -154 | -48 | -445 | -129 | -287 |
| Free Cash Flow | -23,181 | -33,505 | -41,759 | -34,947 | -32,684 |